<DOC>
	<DOCNO>NCT00991926</DOCNO>
	<brief_summary>The beneficial effect plasma lipid Orlistat , selective gastrointestinal lipase inhibitor , largely independent weight loss , might include differential effect plasma non-esterified fatty acid ( NEFA ) . Apart well-known effect insulin resistance pathogenesis , elevate NEFA level probably play also important role peripheral level pathogenesis Growth Hormone ( GH ) insufficiency obesity . Aim observational , mono-centre , randomize , simple-blind , cross-over study verify short-term treatment Orlistat may result decline NEFA circulating level use conjunction low-fat diet effect may restore endogenous activity GH/ Insulin-like growth factor ( IGF ) -1 axis , context GH regulation lipoprotein metabolism , thus add benefit Orlistat obesity cross-linked neuroendocrine metabolic dearrangement .</brief_summary>
	<brief_title>Growth Factor/Insulin-like Growth Factor ( GH/IGF ) -1 Axis Obese Subjects Treatment With Orlistat</brief_title>
	<detailed_description>Subjects : Twenty obese postmenopausal woman ( age : 53.6±6.2 ; BMI : 34.1±4.0 . Subjects recruit , evaluate , monitor Endocrinology Unit Department Molecular Clinical Endocrinology Oncology . Before start study , subject underwent initial screen assessment include medical history , physical examination , laboratory parameter , body weight . Treatment protocol : At study entry plasma sample obtain fast plasma glucose , insulin , lipaemia ( total , HDL LDL cholesterol , tryglycerides ) , GH , IGF-1 , IGFBP-3 . The subject randomize two group treatment : 10 subject receive normo-caloric diet plus + orlistat ( Xenical , Roche , UK ) dose 120 mg tid ; 10 subject receive normo-caloric diet without additional treatment . The duration follow-up 10 day treatment period , without wash-out two period . Each patient assign group . Dynamic test performed end period follow : glucose , insulin OGTT ; GH GHRH + arginine ( GHRH+ARG ) ; post-prandial lipaemia standard fat-rich meal . During study period , subject maintain usual pattern physical activity . Subjects investigator remain unaware laboratory result end study . Methods At baseline end period treatment , follow parameter also measure : 1 . Anthropometric measurement , perform subject wear underwear without shoe . Standing height measure near cm use wall-mounted stadiometer . Body weight determine near 50 g use calibrate balance beam scale . Body mass Index ( BMI ) calculate weight ( kg ) divide height square ( m2 ) use index obesity . Measurements waist circumference , measure adipose tissue distribution cardiovascular disease risk take mid-point umbilicus xiphoid . 2 . Body composition determine conventional Bioelectrical Impedance Analysis ( BIA ) Impedance Vector Analysis ( BIVA ) . Resistance ( R ) reactance ( Xc ) measure single investigator single-frequency 50 kHz bioelectrical impedance analyzer ( BIA 101 RJL , Akern Bioresearch , Firenze , Italy ) accord standard tetrapolar technique . All evaluation perform operator blind respect subject treatment . 3 . Blood sample obtain 08:00 h 09:00 h antecubital vein overnight fast , patient rest position . Blood sample hormonal determination promptly centrifuge , serum separate stored -20 C assay . Blood glucose level determine glucose oxidase method immediately OGTT . The OGTT perform use 75 g dextrose . Blood sample obtain 0 , 30 , 60 , 90 , 20 , 150 , 180 minute plasma glucose insulin measurement . The normal glycemic response OGTT define accord criterion Expert Committee Diagnosis Classification Diabetes Mellitus . Total HDL-cholesterol , triglyceride concentration assay plasma enzymatic colorimetric method ( Roche Molecular Biochemicals ) autoanalyzer Cobas Mira ( ABX Diagnostics ) . LDL-cholesterol calculate use Friedewald formula . Changes lipid profile also analyze calculate total/HDL cholesterol ratio . Plasma NEFA concentration analyze enzymatic colorimetric method ( Wako Chemicals ) . Serum insulin c-peptide measure solid-phase chemiluminescent enzyme immunoassay use commercially available kit ( Immunolite Diagnostic Products Co , Los Angeles , CA , USA ) . The sensitivity assay 0.1 0.3 ng/mL . The intra- interassay coefficient variation ( CVs . ) 2.2 5.8 % , respectively insulin 6.3 8.8 % , respectively c-peptide . The GHRH ( 1-29 , Geref , Serono , Rome , Italy ) + ARG ( arginine hydrochloride , Salf , Bergamo , Italy ) perform . The GH response ARG+GHRH classify deficient ( GHD ) GH peak &lt; 4.2 µg/L sufficient ( GHS ) GH peak &gt; 4.2 µg/L . Serum GH level measure immunoradiometric assay ( IRMA ) use commercially available kit ( HGH-CTK-IRMA , Sorin , Saluggia , Italy ) . The sensitivity assay 0.02 µg/L . The intra- interassay coefficient variation ( CVs . ) 4.5 7.9 % , respectively . Circulating IGF-I level measure IRMA ethanol extraction use Diagnostic System Laboratories Inc. ( Webster , Texas , USA ) . The normal range 31-40 , 41-50 51-60 yr old woman 100-390 , 96-288 , 90-250 µg/l , respectively . The sensitivity assay 0.8 µg/l . The intra-assay CVs 3.4 , 3.0 1.5 % low , medium high point standard curve , respectively . The inter-assay CVs 8.2 , 1.5 3.7 % low , medium high point standard curve . For purpose study , IGF-I level classify normal high -2 SD deficient low -2 SD . The IGFBP-3 assay sensitivity 0•04 ng/l ; normal range adult female population age range study population 2.7-5.6 mg/L . The value molecular mass IGF-I IGFBP-3 use calculation 7.649 kDa 28.5 kDa , respectively.25 Post-prandial lipaemia evaluate morning , ≥ 12 h fasting , 8 h follow standard meal ( 2 , 4 , 6 8 ) h. The standard meal consist potato gateau ( pie make mash potato , whole milk , egg , cheese , ham butter ) consume 15-20 min . The meal , provided 4090 kJ , compose 34 % carbohydrate , 51 % fat ( 34 % saturated fat ) 15 % protein .</detailed_description>
	<mesh_term>Orlistat</mesh_term>
	<criteria>woman postmenopausal age class III obesity normal thyroid , liver , kidney function type 2 diabetes mellitus use hypolipaemic agent</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>obesity</keyword>
	<keyword>GH/IGF-1 axis</keyword>
	<keyword>postprandial NEFA</keyword>
</DOC>